Although PD-1/PDL-1 inhibitors have good antitumor effects and have been approved by the US Food and Drug Administration for various tumor types, their efficacy is challenged by several factors (Chen and Han, 2015; Sheng et al., 2018), such as the tumor immunosuppressive microenvironment. This evidence concerns the gene CD274 and neoplasm.